Tafenoquine

Edina Avdic, Pharm.D.
Tafenoquine is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

Pediatrics Central

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Two different brand names were FDA approved in 2018 
  • Krintafel™- Radical cure (prevention of relapse) of Plasmodium vivax malaria in patients ≥16 years old who are receiving appropriate antimalarial therapy for acute P. vivax infection.
    • Please note that tafenoquine is NOT indicated for the treatment of acute P. vivax malaria.
  • Arakoda™-prophylaxis of malaria in patients ≥18 years of age

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: January 2, 2019

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Tafenoquine ID - 540701 A1 - Avdic,Edina,Pharm.D. Y1 - 2019/01/02/ BT - Johns Hopkins ABX Guide UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540701/all/Tafenoquine PB - The Johns Hopkins University DB - Pediatrics Central DP - Unbound Medicine ER -